Related references
Note: Only part of the references are listed.Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm
K. Kim et al.
OSTEOPOROSIS INTERNATIONAL (2014)
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures
L. Si et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider
Matt D. Stevenson et al.
PHARMACOECONOMICS (2014)
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment
Mickael Hiligsmann et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Health Technology Assessment in Osteoporosis
Mickael Hiligsmann et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision
Kazem Alzahouri et al.
JOINT BONE SPINE (2013)
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women
Mickael Hiligsmann et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Cost-Effectiveness of Alendronate for the Treatment of Osteopenic Postmenopausal Women in Japan
Kensuke Moriwaki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Intervention thresholds for denosumab in the UK using a FRAXA®-based cost-effectiveness analysis
O. Strom et al.
OSTEOPOROSIS INTERNATIONAL (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
PHARMACOECONOMICS (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
VALUE IN HEALTH (2013)
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
Mickael Hiligsmann et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2013)
Osteoporosis in the European Union: medical management, epidemiology and economic burden
E. Hernlund et al.
ARCHIVES OF OSTEOPOROSIS (2013)
Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
Anju Parthan et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2013)
Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
Josep Darba et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
Daniel R. Murphy et al.
BMC MUSCULOSKELETAL DISORDERS (2012)
Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland
K. Lippuner et al.
OSTEOPOROSIS INTERNATIONAL (2012)
A systematic review of hip fracture incidence and probability of fracture worldwide
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2012)
The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis
Mickael Hiligsmann et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2012)
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada
D. Chau et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Cost-Effectiveness of Oral Bisphosphonates for Osteoporosis at Different Ages and Levels of Life Expectancy
Annalise N. Pham et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)
Cost-effectiveness of bazedoxifene incorporating the FRAXA® algorithm in a European perspective
F. Borgstrom et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
B. Jonsson et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Partial adherence: a new perspective on health economic assessment in osteoporosis
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
Mickael Hiligsmann et al.
PHARMACOECONOMICS (2011)
Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
David C. Hoaglin et al.
VALUE IN HEALTH (2011)
ISPOR States Its Position on Network Meta-Analysis
A. E. Ades
VALUE IN HEALTH (2011)
A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence
Susan Ross et al.
VALUE IN HEALTH (2011)
The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands
R. Akehurst et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
Mickael Hiligsmann et al.
BONE (2010)
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years
Mickael Hiligsmann et al.
BONE (2010)
Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer
M. Ivergard et al.
BONE (2010)
FRAX® and its applications in health economics-Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example
O. Strom et al.
BONE (2010)
Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age
Ego Seeman et al.
BONE (2010)
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications
Mickael Hiligsmann et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis
Patrice Fardellone et al.
JOINT BONE SPINE (2010)
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis
F. Borgstrom et al.
OSTEOPOROSIS INTERNATIONAL (2010)
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXA®
F. Borgstrom et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women
M. Hiligsmann et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
J. -J. Body et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Does the Funding Source Influence the Results in Economic Evaluations? A Case Study in Bisphosphonates for the Treatment of Osteoporosis
Rachael L. Fleurence et al.
PHARMACOECONOMICS (2010)
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis
Melissa Thompson et al.
VALUE IN HEALTH (2010)
Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
Mickael Hiligsmann et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2010)
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective
Jean-Blaise Wasserfallen et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis
Fredrik Borgström et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis
Patrizia Berto et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2010)
The Cost-effectiveness of Hormone Therapy in Younger and Older Postmenopausal Women
Shelley R. Salpeter et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
Veronique Rabenda et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Cost-Effectiveness of Hormone Therapy in the United States
Ingrid Lekander et al.
JOURNAL OF WOMENS HEALTH (2009)
Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis
Mickael Hiligsmann et al.
VALUE IN HEALTH (2009)
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK -: Results based on the Women's Health Initiative randomised controlled trial
Ingrid Lekander et al.
BONE (2008)
The cost-effectiveness of alendronate in the management of osteoporosis
John A. Kanis et al.
BONE (2008)
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and-The Netherlands
Jeroen P. Jansen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis
Hansheng Ding et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2008)
FRAX™ and the assessment of fracture probability in men and women from the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Case finding for the management of osteoporosis with FRAX® -: assessment and intervention thresholds for the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis
D. T. Grima et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model
N. Zethraeus et al.
OSTEOPOROSIS INTERNATIONAL (2007)
The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis - A structured review of the literature
Rachael L. Fleurence et al.
PHARMACOECONOMICS (2007)
Bias in published cost effectiveness studies: systematic review
CM Bell et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
RL Fleurence et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Good practice guidelines for decision-analytic modelling in health technology assessment - A review and consolidation of quality assessment
Z Philips et al.
PHARMACOECONOMICS (2006)
Quality of systematic reviews of economic evaluations in health care
T Jefferson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis
N Zethraeus et al.
OSTEOPOROSIS INTERNATIONAL (2002)
Share Paper
